Analytical Data
-
Gene name
ERCC1
- Application
-
Alternative Names
UV20; DNA excision repair protein ERCC-1
-
Species
Human
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P07992
-
Expression Region
Met1~Pro297
-
Molecular Weight
48kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ERCC1 (Excision Repair Cross-Complementation Group 1) is a critical protein involved in the nucleotide excision repair (NER) pathway, which is essential for the repair of DNA damage caused by various environmental factors, such as UV radiation and chemical agents. Mutations or dysfunctions in ERCC1 can lead to increased susceptibility to DNA damage and contribute to the development of various diseases, including cancer and genetic disorders like Xeroderma Pigmentosum. Moreover, ERCC1 plays a significant role in the repair of interstrand crosslinks, making it vital for maintaining genomic stability. Recent research has focused on the role of ERCC1 as a potential biomarker for predicting the efficacy of chemotherapy and radiotherapy, particularly in cancers such as non-small cell lung cancer (NSCLC) and ovarian cancer. Studies have shown that high levels of ERCC1 expression are associated with resistance to platinum-based therapies, leading to the investigation of ERCC1 inhibitors as a promising approach to sensitize tumors and enhance treatment outcomes. Additionally, understanding the molecular mechanisms that regulate ERCC1 expression and its interaction with other repair proteins can provide insights into novel therapeutic targets. This growing body of research underscores the importance of ERCC1 not only in DNA repair but also in clinical applications, paving the way for improved strategies in cancer treatment and management.
